Copy Link Print Information

PLX5622

98 Cited Publications
Avis client

Based on 98 publication(s) in Google Scholar

PLX5622 is a highly selective brain penetrant and orally active CSF1R inhibitor (IC50=0.016 μM; Ki=5.9 nM). PLX5622 allows for extended and specific microglial cells elimination, preceding and during pathology development. PLX5622 demonstrates desirable PK properties in varies animals. PLX5622 is predominantly administered via ad libitum diets with a dose of 1200 ppm.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

  • Pureté: 99.79%
  • CAS No.: 1303420-67-8
  • Formule: C21H19F2N5O
  • Masse moléculaire:395.41
  • Stockage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 1 year , -20°C, 6 months
  • PLX5622 Chemical Structure
    PLX5622 Chemical Structure
  • Experimental Validation Results for PLX5622
  • Experimental Validation Results for PLX5622
  • Experimental Validation Results for PLX5622
  • Experimental Validation Results for PLX5622
  • Experimental Validation Results for PLX5622
  • Experimental Validation Results for PLX5622
  • Experimental Validation Results for PLX5622
CAS No.: 1303420-67-8
Size
Prix
Stock
Quantité
Amount: USD 0.00
Please select quantity
or
or

* Veuillez sélectionner la quantité avant d'ajouter des articles.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of PLX5622:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Trouvez votre distributeur local Your local distributor: Hycultec GmbHHycultec
  • Activité biologique
  • Chemical Information
  • Solvant et solubilité
  • Pureté et documentation
  • Références
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) PLX5622

More
Customer Validation & Images
IFIn Vivo Efficacy StudyFlow CytometryBio/Physico-chemical Assay
  • IF
  • In Vivo Efficacy Study
  • IF
  • Flow Cytometry
  • Bio/Physico-chemical Assay
  • IF
Keywords
MOQ
Minimum order quantity
100 mg

Obtenir un devis En stock

Other size
Obtenir un devis
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Enregistrer
Sign in to MedChemExpress
Enregistrer un nouveau compte

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • PLX5622 Chemical Structure
    PLX5622 Chemical Structure
    1/16
  • 1/16

    MedChemExpress Validation
    PLX5622 were mixed in AIN-76A feed with a dosage of 1200 ppm. C57BL/6 male mice (11-12 weeks) were fed with PLX5622 (1200 ppm) AIN-76A diet ad libitum. Brain tissues were obtained after 7/14 days. The expression of IBA1+ (a marker of microglia) was detected by immunofluorescence. The number of IBA1+ cells was counted using Image J. The results showed that PLX5622 (HY-114153) in AIN-76A Diet (1200 ppm) could effectively eliminate microglias.

  • 1/16

    PLX5622 purchased from MedChemExpress. Usage Cited in: Nature. 2025 Jul;643(8071):509-518. [Abstract]

    Customer Validation
     PLX5622 (1200 ppm; Fed diet). IBA1-expressing microglia/macrophages in the brainstem of Rag2−/− recipients of CD4-tdTomato+ TCR7B8 CD4 T cells 6 to 7 weeks after transfer.

  • 1/16

    PLX5622 purchased from MedChemExpress. Usage Cited in: Nature. 2025 Jul;643(8071):509-518. [Abstract]

    Customer Validation
     PLX5622 (1200 ppm; Fed diet). Neurological score of Csf2-deficient or Csf2-sufficient TCR7B8 transferred hosts with or without CSF1R inhibitor treatment.

  • 1/16

    PLX5622 purchased from MedChemExpress. Usage Cited in: Nat Metab. 2025 Sep 23. [Abstract]

    Customer Validation
     PLX5622 (1200 mg/kg; Fed diet). MBP immunostaining revealing enhanced white matter repair (reduced MBP+ area loss) in the striatum of PLX-treated MCAO mice compared to vehicle controls.

  • 1/16

    PLX5622 purchased from MedChemExpress. Usage Cited in: Nat Metab. 2025 Sep 23. [Abstract]

    Customer Validation
     PLX5622 (1200 mg/kg; Fed diet). PLX treatment significantly depleted the microglial population following MCAO. n = 3 mice/group.

  • 1/16

    PLX5622 purchased from MedChemExpress. Usage Cited in: Nat Metab. 2025 Sep 23. [Abstract]

    Customer Validation
     Efavirenz (EFV) (0.09 mg/kg; i.g.; once daily) treatment significantly downregulated pro-inflammatory transcripts of microglia in MCAO mice.

  • 1/16

    PLX5622 purchased from MedChemExpress. Usage Cited in: Immunity. 2024 Oct 9:S1074-7613(24)00458-8. [Abstract]

    Customer Validation
     PLX5622 (0.12%; Fed diet). Tile scan images and magnified images show MX04 (gray) labeling for plaque visualization in injected areas as well as IBA1 (magenta) and CD68 (cyan) staining.

  • PLX5622